AVIEW LCS vs CAC Software
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your clinical workflow demands an integrated AI solution for comprehensive cardiopulmonary assessment, including automated lung nodule detection, COPD quantification, and coronary artery calcification scoring from a single low-dose CT scan. This platform is ideal for institutions seeking to streamline lung cancer screening programs while simultaneously leveraging the same scan for broader cardiovascular and pulmonary health insights, including automated nodule follow-up comparisons.
View AVIEW LCS →Choose CAC Software if…
Choose Imbio's CAC Software if your primary focus is on robust, dedicated quantification of coronary artery calcification for cardiovascular risk assessment using non-contrast chest CT scans. This tool is best suited for scenarios where precise Agatston scores, arterial age, and detailed 3D visualizations of calcification are paramount, integrating efficiently into existing DICOM viewing workflows for specialized cardiology applications.
View CAC Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | CAC Software |
|---|---|---|
| Pricing | Contact for pricing | Unknown |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Cloud-based (SaaS), integrates with PACS |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CAC SoftwareBoth tools emphasize automation and integration into existing radiology workflows. However, Tool B explicitly states 'No stand-alone workstations, no user interfaces to learn' and 'returns results without user intervention,' suggesting a simpler, less disruptive integration into a radiologist's daily routine by minimizing direct user interaction. Tool A also focuses on workflow streamlining and automated reporting, including patient-friendly reports, and claims significant workload reduction.
Clinical Value
AVIEW LCSTool A offers a significantly broader clinical scope by providing integrated analysis for lung cancer screening (nodules, Lung-RADS), COPD (emphysema quantification), and coronary artery calcification from a single low-dose CT scan. This multi-modal assessment provides comprehensive cardiopulmonary insights, enhancing overall diagnostic value beyond a single disease focus. Tool B, while effective for CAC, is specialized in that area.
Pricing & Value
AVIEW LCSWhile both tools require direct contact for pricing, Tool A's comprehensive 3-in-1 analysis for lung cancer, COPD, and coronary artery calcification from a single scan inherently offers significantly higher value. This integrated approach can lead to greater efficiency and a more holistic patient assessment, potentially providing more clinical insights for a single investment compared to a specialized tool.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, BAA availability, and flexible deployment options (cloud, on-premise, hybrid/local). Both also emphasize integration with existing PACS/RIS and DICOM workflows. Tool A lists a broader range of international regulatory clearances, while Tool B highlights a strong network of channel partners, balancing their enterprise appeal.
Innovation
AVIEW LCSWhile both leverage AI and deep learning for automated analysis, Tool A demonstrates greater innovation through its integrated, multi-modal assessment of lung cancer, COPD, and coronary artery calcification from a single CT scan. Its ability to automatically compare nodules in follow-up scans and precisely calculate Volume Doubling Time for risk tracking represents a more advanced and comprehensive approach to patient management.
Support & Docs
CAC SoftwareImbio (Tool B) provides more explicit details regarding its support structure, including specific support hours, multiple phone lines (US and India), and a clear process for requesting documentation and submitting support cases online. While Coreline Soft (Tool A) lists contact information for a customer service team, Imbio's published details suggest a more structured and transparent support offering.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | CAC Software |
|---|---|---|
| Product Name | AVIEW LCS | CAC Software |
| Company | Coreline Soft Co. | Imbio |
| Tagline | AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment | AI-powered medical imaging analysis for personalized lung and cardiothoracic care. |
| Primary Clinical Focus | Detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from low-dose CT scans. | Determination of location and quantification of calcification within coronary arteries from non-contrast chest CT scans. |
| Key Analytical Features | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans, Comprehensive, automated report generation, Integration with PACS/RIS and third-party platforms. | Automated image post-processing for coronary artery calcification, Quantification of calcification within coronary arteries, Outputs Agatston score, arterial age, calcified lesion mass and volume, Provides 3D visualizations and annotated images, Non-invasive analysis from non-contrast chest CT scans, Integrates into existing DICOM viewing workflow, Supports risk assessment for coronary artery disease, Deep-learning based analysis. |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and CAC Software.